Kane receives U.S. patent for Dispersin

Kane Biotech (TSX-V:KNE) has received a new U.S. patent that specifically protects the use of its Dispersin technology in various types of wound care products that the company is currently developing. This is the fifth patent Kane has on Dispersin, including two in the U.S., one in Australia and two in New Zealand. “It would [...]

Kane’s DispersinB passes biocompatibility tests

Kane Biotech’s (TSX-V:KNE) DispersinB’s topical wound spray has passed FDA-recommended cytotoxicity, primary skin irritation and genotoxicity tests, with two remaining biocompatibility studies currently in progress. “Biocompatibility is critical to the commercial development of a topical wound care product and these results confirm that DispersinB spray is non-cytotoxic, non-irritant, non-mutagenic and non-genotoxic,” CSO Dr. Sri Madhyastha [...]

Kane gets DispersinB from biotech plants

Kane Biotech (TSX-V:KNE) has confirmed the invention of biotech plants producing DispersinB antibiofilm enzyme, representing a proof of concept for developing bacterial disease-resistant agricultural crops. The Company said DispersinB-expressing plants are resistant to plant pathogens due to their ability to inhibit and disrupt biofilms. In addition, this biotech plant can also be used as a [...]

In conversation with Gord Froehlich

After a 25-year stint with Monsanto Canada, where he rose to vice president, Gord Froehlich moved seamlessly into Kane Biotech (TSX-V: KNE) as VP of Business Development and then into the executive suite in 2006. While there is a myriad of differences between a biotech start-up and a global ag-biotech giant, Mr. Froehlich contends that [...]